Immediate vs. delayed androgen deprivation for prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Androgen ablation has been the standard treatment for metastatic prostate cancer for over 50 years.
• Prostate-specific antigen (PSA) testing has led to earlier diagnosis and stage migration, altering historical treatment paradigms.
• The widespread use of radical therapies has increased the complexity of timing endocrine treatment.

Purpose of the Study:

• To review historical and current data on androgen ablation and PSA testing in prostate cancer.
• To provide practical considerations for the timing of endocrine treatment in modern prostate cancer management.
• To address the challenges posed by advanced prostate cancer diagnoses in the PSA era.

Main Methods:

• Compilation of data from past literature and ongoing modern studies.
• Review of treatment strategies for symptomatic metastatic prostate cancer.
• Analysis of the impact of PSA testing on disease presentation and treatment timing.

Main Results:

• Historical studies pre-PSA era have limited relevance for current patient counseling.
• Advanced prostate cancer is now diagnosed at earlier stages and even as isolated PSA elevation post-treatment.
• Lack of clear guidelines necessitates practical considerations for endocrine treatment timing.

Conclusions:

• Current clinical practice for prostate cancer requires updated approaches to endocrine treatment timing.
• The evolution of diagnostic tools like PSA necessitates a re-evaluation of established treatment protocols.
• Further research and guideline development are needed to optimize prostate cancer management.